CoV-AbDab：冠状病毒抗体数据库。

CoV-AbDab: the coronavirus antibody database.

机构信息

Oxford Protein Informatics Group, Department of Statistics, University of Oxford, Oxford OX1 3LB, UK.

出版信息

Bioinformatics. 2021 May 5;37(5):734-735. doi: 10.1093/bioinformatics/btaa739.

DOI:10.1093/bioinformatics/btaa739

PMID:32805021

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7558925/

Abstract

MOTIVATION

The emergence of a novel strain of betacoronavirus, SARS-CoV-2, has led to a pandemic that has been associated with over 700 000 deaths as of August 5, 2020. Research is ongoing around the world to create vaccines and therapies to minimize rates of disease spread and mortality. Crucial to these efforts are molecular characterizations of neutralizing antibodies to SARS-CoV-2. Such antibodies would be valuable for measuring vaccine efficacy, diagnosing exposure and developing effective biotherapeutics. Here, we describe our new database, CoV-AbDab, which already contains data on over 1400 published/patented antibodies and nanobodies known to bind to at least one betacoronavirus. This database is the first consolidation of antibodies known to bind SARS-CoV-2 as well as other betacoronaviruses such as SARS-CoV-1 and MERS-CoV. It contains relevant metadata including evidence of cross-neutralization, antibody/nanobody origin, full variable domain sequence (where available) and germline assignments, epitope region, links to relevant PDB entries, homology models and source literature.

RESULTS

On August 5, 2020, CoV-AbDab referenced sequence information on 1402 anti-coronavirus antibodies and nanobodies, spanning 66 papers and 21 patents. Of these, 1131 bind to SARS-CoV-2.

AVAILABILITYAND IMPLEMENTATION

CoV-AbDab is free to access and download without registration at http://opig.stats.ox.ac.uk/webapps/coronavirus. Community submissions are encouraged.

SUPPLEMENTARY INFORMATION

Supplementary data are available at Bioinformatics online.

摘要

动机

一种新型β冠状病毒（SARS-CoV-2）的出现导致了一场大流行，截至 2020 年 8 月 5 日，该大流行病已导致超过 70 万人死亡。世界各地正在进行研究，以开发疫苗和疗法来最大限度地降低疾病传播和死亡率。这些努力的关键是对 SARS-CoV-2 的中和抗体进行分子特征分析。这些抗体对于衡量疫苗的功效、诊断暴露情况以及开发有效的生物疗法非常有价值。在这里，我们描述了我们的新数据库 CoV-AbDab，该数据库已经包含了超过 1400 种已发表/已获得专利的抗体和纳米抗体的数据，这些抗体和纳米抗体已知可与至少一种β冠状病毒结合。该数据库是第一个整合了已知可与 SARS-CoV-2 以及其他β冠状病毒（如 SARS-CoV-1 和 MERS-CoV）结合的抗体的数据库。它包含了相关的元数据，包括交叉中和的证据、抗体/纳米抗体的起源、完整的可变区序列（如有）和胚系分配、表位区域、与相关 PDB 条目、同源模型和来源文献的链接。